

Japan Langerhans Cell Histiocytosis Study Group (JLSG)-96 Protocol

Protocol A (induction and maintenance therapy for newly diagnosed patients)

Induction Arm A: Ara-C, VCR, and PSL

Ara-C (100 mg/m² per day as a 6-h drip) on Days 1–5

VCR (0.05mg/kg per day IV) on Day1

PSL (2 mg/kg per day orally) on Days 1–5

Every 2 wk x 3 courses

Maintenance Arm A

a) Ara-C, VCR, and PSL

Ara-C (150 mg/m² per d as a 2-h drip) on Day 1

VCR (0.05mg/kg per d IV) on Day1

PSL (2 mg/kg per d orally) on Days 1–4

b) MTX and PSL

MTX (1 mg/kg per d IV) on Day1

PSL (2 mg/kg per d orally) on Days 1–3

Alternate every 2 wk (a,b,a,b,a,b,a,b,a,b) for 24 wk

Protocol B (salvage therapy for poor responders to Induction Arm A)

Induction Arm B: ADR, CPM, VCR, and PSL

ADR (35 mg/m² per d IV) on Day 1

CPM (10 mg/kg per d IV) on Days 1–5

VCR (0.05 mg/kg per d IV) on Day 1

PSL (2 mg/kg per d orally) on Days 1–5

Every 2 wk x 3 courses

Maintenance Arm B

a) ADR, VCR, and PSL

ADR (35 mg/m² per d IV) on Day 1

VCR (0.05 mg/kg per d IV) on Day 1

PSL (2 mg/kg per d orally) on Days 1–5

b) MTX and PSL

MTX (3 mg/kg per d as a 1-h drip) on Day 1

PSL (2 mg/kg per d orally) on Days 1–3

c) CPM, VCR, and PSL

CPM (10 mg/kg per d IV) on Day 1

VCR (0.05 mg/kg per d IV) on Day 1

PSL (2 mg/kg per d orally) on Days 1–5

Alternate every 2 wk (a,b,c,b,a,b,c,b,a,b,c,b) for 24 wk

Abbreviation: Ara-C, cytosine arabinoside; VCR, vincristine; PSL, prednisolone; IV, intravenous; MTX, methotrexate; ADR, doxorubicin; CPM, cyclophosphamide.